Category: Uncategorized

    Is Drug Repurposing the new breakthrough for faster approval of Psychedelic-assisted treatments? In this TDR Psychedelic Exclusive, we speak with the CEO of Algernon Pharmaceuticals (CNSX: AGN) (OTC: AGNPF) Christopher Moreau who explains the company’s recent announcement involving a Phase 2 trial with DMT pertaining to Traumatic Brain Injury, otherwise known as TBI, which will strengthen the potential of DMT’s healing effects in supporting the brain’s natural rewiring functions to recover from TBIs like stroke. The company’s advancements are towards drug repurposing for new disease applications, and Moreau expounds how this is a crucial phase not just for …

    CEO Christopher J. Moreau provides an update on Algernon Pharmaceuticals Inc. announcement that its subsidiary Algernon NeuroScience (AGN Neuro) has added a new clinical research program for the treatment of Traumatic Brain Injury (TBI) with AP-188 (“N,N-Dimethyltryptamine or DMT”). AGN Neuro plans to be the first company globally to investigate DMT for TBI in humans and is planning to begin a Phase 2 clinical trial in Q4, 2023. About Algernon NeuroScience Algernon NeuroScience is a private equity subsidiary of Algernon Pharmaceuticals and has been created to advance the Company’s DMT stroke and traumatic brain injury research program. AGN Neuro …

  Algernon Pharmaceuticals CEO Christopher J. Moreau joined Steve Darling from Proactive to share news the Company’s subsidiary Algernon NeuroScience has announced it has completed the first dosing in its Phase 1 clinical study of an intravenous formulation of AP-188 or DMT. Mr. Moreau explains to Proactive that the safety review committee has approved moving the study forward with an escalated dose after observing no safety or tolerability issues. This study will include up to 60 healthy volunteers enrolled in total, which will include both psychedelic experienced and psychedelic naïve subjects. Phase 2 acute stroke and rehabilitation studies are expected …

  “Drug Could Possibly Both Reduce Acute Damage of the Stroke” – How DMT Could be the Future of Stroke Treatment     Dr Rick Strassman, one of the most well-known researchers and authors on DMT, shares with SR Times his expert knowledge on using DMT as a treatment for stroke. DMT (N.N-Dimethyltryptamine) is a hallucinogenic tryptamine drug which naturally occurs in plant species such as Psychotria viridis or Chacruna. It can also be made in a laboratory. How did the concept of using DMT as a stroke treatment develop? Several papers emerged from Hungary, published by Ede Frecksa and …

  Radius Research Interview – Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau – Ifendprodil Program Update Targeting Chronic Cough     CEO Christopher J. Moreau provides an update on the Company’s Ifendprodil drug program targeting chronic cough. The Company is planning a phase 2b study for later this year. About Algernon Pharmaceuticals Inc. Algernon Pharmaceuticals is a Canadian clinical stage drug development and repurposing company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals has active research programs for IPF with chronic cough, and chronic kidney disease, and is the parent company of a newly created private subsidiary called Algernon …

  Radius Research – Algernon Pharma (AGN) CEO Chris Moreau – AP-188 DMT Dimethyltryptamine Program Update     Algernon Pharmaceuticals CEO Christopher J. Moreau provides update on AP-188 DMT (Dimethyltryptamine) Stroke Program. Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study https://www.globenewswire.com/news-re… About Algernon NeuroScience Algernon NeuroScience is a private equity subsidiary of Algernon Pharmaceuticals and has been created to advance the Company’s DMT stroke research program. AGN Neuro has filed a Form 1-A offering statement with the U.S. Securities and Exchange Commission, seeking qualification to raise up to USD $10M for AGN Neuro by offering up …

    Canadian clinical-stage psychedelics company Algernon PharmaceuticalsAGNPF’s newly created subsidiary Algernon NeuroScience (AGN Neuro) has dosed the first subject in its Phase 1 clinical study of proprietary IV formulation of DMT, AP-188. The trial is being conducted at the Centre for Human Drug Research in Leiden, the Netherlands. Renowned psychopharmacologist and Algernon consultant Prof. David Nutt commented that, while “a significant number of promising stroke drugs have failed because they were focused on trying to be neuroprotective of the brain during a stroke,” preclinical data shows that “DMT is promoting neuroplasticity, a key mechanism in recovery once the stroke …

  Microdose: Microdosing DMT to Treat Stokes: Not as Trippy as it Sounds     On January 17th, the company Algernon Pharmaceuticals (CSE: AGN, OTCQB: AGNPF) announced that they had dosed the first patient in their Phase 1 safety trial of the psychedelic drug DMT. The company eventually hopes to use small, non-hallucinogenic doses of DMT — DMT microdoses in other words — to treat stroke patients. Known for its extremely powerful psychedelic effects — a common experience is having your consciousness transported to another “realm” where you interact with alien-like beings — DMT is one of the least scientifically studied hallucinogenic drugs. …

Proactive Investors CEO Interview – Algernon NeuroScience Doses First Patient in Stroke Study     Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news that the Company has announced its subsidiary, Algernon NeuroScience, has dosed the first subject in the Phase 1 DMT clinical stroke study. Algernon is the very first company in the world to investigate DMT for stroke. Mr. Moreau explains that the dosing took place in the Netherlands where the study is being conducted at the Centre for Human Drug Research in Leiden. This study is to use a single-escalating dose design aimed …

  Algernon Pharmaceuticals Announces Upcoming Phase 2b Chronic Cough Study of Ifenprodil     In the video interview above, and article which follows, Algernon Pharmaceuticals CEO Christopher J. Moreau shares that the Company (AGN) has announced plans for a 180-patient, 90-day Phase 2b clinical study of NP-120 for chronic cough in Q3 of 2023. Ifenprodil represents a novel first-in-class potential treatment for chronic cough and is thought to interfere with central signalling in the brain, suppressing the urge to cough. The decision to advance the study is based on positive data previously reported on July 28, 2022, from the company’s …